Summary & Overview
HCPCS Q2053: Brexucabtagene Autoleucel CAR T-Cell Therapy
HCPCS Level II code Q2053 identifies brexucabtagene autoleucel, an autologous anti-CD19 CAR T-cell therapy product that includes leukapheresis and dose preparation per therapeutic dose. As a high-cost, precision biologic used in oncology, this code is central to billing for CAR T therapies and influences coverage, prior authorization, and site-of-care decisions nationwide. Major payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical and billing scope of Q2053, typical sites of care, and what payers commonly consider when processing claims for CAR T-cell products. The publication outlines typical billing elements, common modifiers, and the operational components captured by the code (product, leukapheresis inclusion, and dose preparation). It also summarizes benchmark and policy topics relevant to high-cost cellular therapies, including reimbursement frameworks and oversight considerations affecting national access. Where specific payer policies or numeric benchmarks are not available in the input, the text notes that data are not available in the input. This summary is intended to orient providers, billing staff, and policy analysts to the coding and administrative context for Q2053 at a national level.
Billing Code Overview
HCPCS Level II code Q2053 represents brexucabtagene autoleucel, a personalized autologous CAR T-cell therapy described as up to 200 million autologous anti-CD19 CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose. This code covers the biologic product and specified associated manufacturing/processing steps required to produce a single therapeutic infusion.
-
Service type: Cell therapy / CAR T-cell therapy product and associated dose preparation
-
Typical site of service: Hospital-based specialty infusion or cellular therapy center, including inpatient or outpatient specialty oncology infusion suites
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) or large B-cell lymphoma is referred for autologous CAR T-cell therapy with brexucabtagene autoleucel. The patient undergoes initial hematology/oncology consultation, determination of eligibility criteria (disease status, prior therapies, organ function, infectious disease screening), and informed consent. Leukapheresis is scheduled to collect autologous peripheral blood mononuclear cells; cells are transported to a manufacturing facility for CAR T-cell transduction and expansion. During manufacturing the patient may receive bridging systemic therapy. On receipt of the manufactured CAR T-cell product, the patient returns for lymphodepleting chemotherapy (typically fludarabine and cyclophosphamide) administered in an inpatient or outpatient infusion center depending on institutional protocol and patient risk. The therapeutic dose of brexucabtagene autoleucel is delivered by intravenous infusion under close monitoring for immediate infusion reactions and for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) over the subsequent days to weeks. Supportive care includes antipyretics, intravenous fluids, tocilizumab and corticosteroids as needed, intensive care if severe CRS/ICANS develops, and ongoing post-infusion disease response assessments. Typical sites of service include an academic medical center, tertiary hospital inpatient unit, or an outpatient cellular therapy infusion center capable of providing specialized monitoring and intensive care escalation if required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |